Wegovy
Brand-name semaglutide FDA-approved for chronic weight management — 2.4 mg weekly injection, with an oral tablet formulation.
Wegovy is Novo Nordisk's weight-management brand of semaglutide, FDA-approved in 2021 for adults with a BMI of 30+, or 27+ with a weight-related condition. The classic format is a once-weekly 2.4 mg pre-filled pen reached through a stepwise escalation from 0.25 mg; trials behind it include STEP 1 (14.9% average loss over 68 weeks) and SELECT (20% relative reduction in major cardiovascular events).
The name also extends to oral semaglutide for weight management — the daily "Wegovy pill" — which averaged about 14% over 64 weeks in its pivotal study. Self-pay list prices run high (around $349/month at starter doses through manufacturer channels), which is why structured telehealth programs, insurance prior authorization, and savings cards dominate the access conversation. Our platform offers both formats from $149/month.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Wegovy? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment